SPEVIGO approved for expanded indications in China and the US SPEVIGO approved for expanded indications in China and the US FDA approval for the Treatment of Generalized Pustular Psoriasis (GPP) in Adults and Pediatric Patients 12 Years of Age and Older Weighing at Least 40kg
Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month Boehringer Ingelheim cap out-of-pocket costs at $35 per month for eligible patients for all of the company’s inhaler products.
Boehringer inhalers now available at $35 a month for eligible patients Boehringer inhalers now available at $35 a month for eligible patients Boehringer COPD and asthma inhalers now available at $35 a month for eligible patients